NCT04676035View on ClinicalTrials.gov

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

January 26, 2022

Study Completion Date

January 26, 2022

Conditions
Prostate Cancer Patients
Interventions
DRUG

Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680

"* Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~* Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27"

Trial Locations (1)

Unknown

Sun Yat-sen Memorial Hospital, Guangzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04676035 - The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole | Biotech Hunter | Biotech Hunter